Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Wiendl, Heinz; Gold, Ralf; Berger, Thomas; Derfuß, Tobias; A. Linker, Ralf; Mäurer, Mathias; Aktaş, Orhan; Baum, Karl; Berghoff, Martin; Bittner, Stefan; Chan, Andrew; Czapliński, Adam; Deisenhammer, Florian; Di Pauli, Franziska; Du Pasquier, Renaud; Enzinger, Christian; Fertl, Elisabeth; Gass, Achim; Gehring, Klaus; Gobbi, Claudio; Goebels, Norbert; Guger, Michael; Haghikia, Aiden; Hartung, Hans‐Peter; Heidenreich, Fedor; Hoffmann, Olaf; Kallmann, Boris; Kleinschnitz, Christoph; Klotz, Luisa; I. Leussink, Verena; Leutmezer, Fritz; Limmroth, Volker; D. Lünemann, Jan; Lutterotti, Andreas; G. Meuth, Sven; Meyding‐Lamadé, Uta; Platten, Michael; Rieckmann, Peter; Schmidt, Stephan; Tumani, Hayrettin; Weber, Frank; S. Weber, Martin; K. Zettl, Uwe; Ziemssen, Tjalf; Zipp, Frauke; the ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG), for

doi:10.1177/17562864211039648

Public

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Published in Therapeutic Advances in Neurological Disorders • Jan 1, 2021

Authors:

Heinz Wiendl

Ralf Gold

Thomas Berger

Abstract

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years h...

Subject

Multiple sclerosis

Medicine

Disease

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!